People in the News

The American College of Medical Genetics and Genomics appointed six new directors, including a new president-elect, to its board at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles this week.

The newly elected directors, who will serve six-year terms from March 2025 to March 2031, are:

• President-Elect Christa Martin, currently CSO at Geisinger and vice dean for research at Geisinger's School of Medicine. Martin earned her PhD in human genetics from the University of Pittsburgh and completed her postdoc at the University of Chicago, where she became board-certified in clinical cytogenetics. At Geisinger, she has pioneered initiatives like the MyCode Community Health Initiative, and was the founding director of Geisinger's Autism & Developmental Medicine Institute.
• Josh Deignan, a board-certified clinical geneticist and clinical professor of pathology and laboratory medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
• Lauren Massingham, a board-certified medical geneticist and current director of the cancer genetic program at Hasbro Children's Hospital and Rhode Island Hospital
• David Miller, a board-certified clinical geneticist who directs the Neurofibromatosis Research Initiative at Boston Children's Hospital, and is also an associate molecular pathologist at Brigham and Women's Hospital.
• Douglas Stewart, a board-certified medical geneticist and internist who serves as a senior investigator at the National Cancer Institute and adjunct investigator at NHGRI.
• William Wilcox, a board-certified clinical geneticist and biochemical geneticist who serves a medical director of the Emory Genetic Clinical Trials Center and is the founder of the Medical Biochemical Genetics Training Program at Emory.

NeoGenomics has promoted Chief Commercial Officer Warren Stone to president and chief operating officer (COO), effective April 1. Stone has over 25 years of general management and commercial experience. In his expanded role, he will be responsible for driving the company's lab operations, data solutions division, and enterprise operations functions. Before joining NeoGenomics in 2022, Stone was president of the Americas at Ortho Clinical Diagnostics and senior VP at MilliporeSigma. He earned his MBA from Suffolk University and has a BASc in analytical chemistry from Technikon Witwatersrand South Africa. Current NeoGenomics COO Melody Harris will leave the firm at the end of May.

Point-of-care testing and therapeutics firm Seek Labs has appointed Kim Wirthlin as its chief strategy officer, effective March 17. She has more than 25 years of experience in university leadership, government relations, academic healthcare, and early-stage company development. Prior to joining Salt Lake City-based Seek Labs, Wirthlin was president and COO of the Huntsman Cancer Foundation. Before that she spent 18 years as a member of the executive management at University of Utah Health.

Hologic said that its general counsel, John Griffin, will retire on May 1 and he will become a special advisor to the company's chairman, president, and CEO. He will be succeeded by Anne Liddy, who is currently the company's assistant general counsel.

The American Clinical Laboratory Association has named the members of its board of directors for 2025 through 2027.

The organization elected William Morice as the chair of its board of directors. Morice is president and CEO of Mayo Collaborative Services/Mayo Clinic Laboratories. Laboratory Corporation of America Chairman, President, and CEO Adam Schechter was elected vice chair. Exact Sciences Chairman and CEO Kevin Conroy was elected treasurer.

Natera CEO Steve Chapman, HealthTrackRx Executive Chairman and CEO Martin Price, and GeneDx President and CEO Katherine Stueland, were elected to the board as first-time members. Jim Davis, chairman, president, and CEO of Quest Diagnostics; Paul Diaz, president and CEO of Myriad Genetics; Cory Roberts, CEO of Sonic Healthcare USA; Chris Smith, CEO of NeoGenomics Laboratories; Andy Theurer, CEO of ARUP Laboratories; Susan Van Meter, president of ACLA; and Elias Zerhouni, president of Opko Health/BioReference Health, were elected as returning members.

VedaBio has appointed Rachel Jones as chief commercial officer to help advance the development and commercialization of its CRISPR-based molecular detection platform. Jones formerly served as CCO at Karius and BioFire Diagnostics.

Danaher announced that it has appointed Charles Lamanna to its board of directors and the board's science and technology committee. Lamanna is currently the corporate VP of business and industry at Microsoft, where he oversees product innovation in artificial intelligence-based business applications, low-code platforms, and autonomous agents. He previously was the founder and CEO of public cloud management solution MetricsHub, which Microsoft acquired in 2013.

Karin Almqvist Liwendahl is stepping down as CFO of Immunovia at the end of the first quarter as the company is shifting its focus to the US market. Jeff Borcherding and the firm's finance team members will take over her responsibilities while Immunovia is searching for a successor.

Bio-Techne has appointed Amy Herr to serve as an independent director on the firm's board and on the board's science and technology committee. Herr is a professor of bioengineering at the University of California, Berkeley and VP of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes. She was previously a cofounder and advisory board member of Zephyrus Biosciences, which Bio-Techne acquired in 2016, and served as the founding executive director of UC Berkeley's Bakar BioEnginuity Hub, an incubator for academic spinout companies.

Roche this week announced that Wafaa Mamilli will join the company as chief digital technology officer and will become a member of the enlarged corporate executive committee. She will take over worldwide responsibility for informatics at Roche from CFO and Chief Informatics Officer Alan Hippe, who will remain as CFO. Mamilli previously served as chief digital and technology officer and group president for China, Brazil, and precision animal health at pharmaceutical firm Zoetis. Before joining Zoetis, she held various international roles at Eli Lilly and Company, including global chief information officer.